PE20020436A1 - Derivados de tetrahidropirano como antagonistas del receptor de neuroquinina 1 (nk-1) - Google Patents
Derivados de tetrahidropirano como antagonistas del receptor de neuroquinina 1 (nk-1)Info
- Publication number
- PE20020436A1 PE20020436A1 PE2001000828A PE2001000828A PE20020436A1 PE 20020436 A1 PE20020436 A1 PE 20020436A1 PE 2001000828 A PE2001000828 A PE 2001000828A PE 2001000828 A PE2001000828 A PE 2001000828A PE 20020436 A1 PE20020436 A1 PE 20020436A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- trifluoromethyl
- neuroquinin
- antagonists
- receptor
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 2
- 150000003527 tetrahydropyrans Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- -1 3,5-BIS (TRIFLUORomethyl) PHENYL Chemical class 0.000 abstract 2
- WZKSXHQDXQKIQJ-UHFFFAOYSA-N F[C](F)F Chemical class F[C](F)F WZKSXHQDXQKIQJ-UHFFFAOYSA-N 0.000 abstract 2
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical group [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 abstract 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical group [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE REFIERE A UN COMPUESTO DE FORMULA I DONDE R1 ES F, TRIFLUOROMETILO; R2 ES F, TRIFLUOROMETILO; R3 ES METILO O HIDROXIMETILO; R4 ES HALOGENO, HIDROXI, ALQUELINO C2-C4, ALQUINILO C2-C4, N3, NR5R6, ENTRE OTROS; R5 ES H, ALQUILO C1-C4, CICLOALQUILO C3-C7, CICLOALQUIL C3-C7 (ALQUILO C1-C4), ALQUILO C2-C4, ENTRE OTROS; R6 ES H, ALQUILO C1-C4, CICLOALQUILO C3-C7, ALQUILO C2-C4, ENTRE OTROS; R5 O R6 JUNTO A N FORMAN UN ANILLO HETEROALIFATICO DE 4 A 7 ATOMOS DE ANILLO; Z ES UN ENLACE, ALQUILENO C1-C6, CICLOALQUILENO C3-C6, ENTRE OTROS, n ES 1-2; p ES 1-2; q ES 1-2. SON COMPUESTOS PREFERIDOS cis,trans-(2R,3S,4R,8R)-2-[1-(3,5-BIS(TRIFLUOROMETIL)FENIL)ETOXI]-3-(3,4-DIFLUOROFENIL)-4-VINILTETRAHIDROPIRANO, trans,trans-(2R,3S,4S,8R)-2-[1-(3,5-BIS(TRIFLUOROMETIL)FENIL)ETOXI]-3-(3,4-DIFLUOROFENIL)-4-VINILTETRAHIDROPIRANO, 2R,3S,4R,8R)-2-[1-(3,5-BIS(TRIFLUOROMETIL)FENIL)ETOXI]-3-(3,4-DIFLUOROFENIL)-TETRAHIDROPIRANO-4-CARBALDEHIDO, ENTRE OTROS. LOS COMPUESTOS MENCIONADOS SON ANTAGONISTAS DEL RECEPTOR DE NEUROQUININA 1 (NK-1) Y SON UTILES PARA EL TRATAMIENTO DE TRASTORNOS DEL SISTEMA NERVIOSO CENTRAL
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0020721.7A GB0020721D0 (en) | 2000-08-22 | 2000-08-22 | Therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20020436A1 true PE20020436A1 (es) | 2002-06-14 |
Family
ID=9898111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2001000828A PE20020436A1 (es) | 2000-08-22 | 2001-08-20 | Derivados de tetrahidropirano como antagonistas del receptor de neuroquinina 1 (nk-1) |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US6489343B2 (es) |
| AU (2) | AU2001278626A1 (es) |
| GB (1) | GB0020721D0 (es) |
| JO (1) | JO2231B1 (es) |
| PE (1) | PE20020436A1 (es) |
| WO (2) | WO2002016343A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001064223A1 (en) * | 2000-02-29 | 2001-09-07 | Merck Frosst Canada & Co. | Method for treating or preventing depression |
| GB0121874D0 (en) * | 2001-09-10 | 2001-10-31 | Merck Sharp & Dohme | Therapeutic agents |
| GB0217068D0 (en) * | 2002-07-23 | 2002-08-28 | Merck Sharp & Dohme | Therapeutic agents |
| WO2004078750A1 (en) * | 2003-03-07 | 2004-09-16 | Merck Sharp & Dohme Limited | Tetrahydropyran compounds as tachykinin antagonists |
| DE602005015253D1 (de) * | 2004-11-22 | 2009-08-13 | Mallinckrodt Inc | Verfahren zur aufreinigung von benzphetaminhydrochlorid |
| ATE429415T1 (de) * | 2004-11-30 | 2009-05-15 | Mallinckrodt Inc | Verfahren zur kristallisierung von benzphetamin |
| WO2006115188A1 (ja) * | 2005-04-22 | 2006-11-02 | Daiichi Sankyo Company, Limited | ヘテロ環化合物 |
| JP5366541B2 (ja) * | 2005-05-25 | 2013-12-11 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | ホルミルテトラヒドロピラン類、それの調製方法、および液晶化合物類の調製におけるそれの使用 |
| EP2117538A1 (en) | 2007-01-24 | 2009-11-18 | Glaxo Group Limited | Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-) |
| FR3002733B1 (fr) | 2013-03-04 | 2015-08-14 | Servier Lab | Nouveau sel de l'abexinostat, forme cristalline associee,leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| CA2960044A1 (en) | 2014-09-03 | 2016-03-10 | Pharmacyclics Llc | Novel salts of 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofuran-2-carboxamide, related crystalline forms, method for preparing the same and pharmaceutical compositions containing the same |
| CN111479809B (zh) * | 2017-12-13 | 2021-10-29 | 劲方医药科技(上海)有限公司 | 一种TGF-βRI抑制剂的晶型、盐型及其制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9301920D0 (en) | 1993-02-01 | 1993-03-17 | Foundation For Ethnobiology Th | Polycetylenes |
| SK283070B6 (sk) * | 1993-12-29 | 2003-02-04 | Merck Sharp & Dohme Limited | Substituované morfolínové deriváty, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie |
| GB9812662D0 (en) * | 1998-06-11 | 1998-08-12 | Merck Sharp & Dohme | Therapeutic use |
| AU4278199A (en) * | 1998-06-11 | 1999-12-30 | Merck Sharp & Dohme Limited | Use of a nk-1 receptor antagonist for treating psychiatric disorders |
| AU4279699A (en) * | 1998-06-11 | 1999-12-30 | Merck Sharp & Dohme Limited | Use of a nk-1 receptor antagonist for treating psychiatric disorders |
| CO5150225A1 (es) | 1999-03-19 | 2002-04-29 | Merck Sharp & Dohme | Derivados del tetrahidropirano y su uso como agentes terapeuticos |
-
2000
- 2000-08-22 GB GBGB0020721.7A patent/GB0020721D0/en not_active Ceased
-
2001
- 2001-08-14 JO JO2001133A patent/JO2231B1/en active
- 2001-08-17 AU AU2001278626A patent/AU2001278626A1/en not_active Abandoned
- 2001-08-17 WO PCT/GB2001/003685 patent/WO2002016343A1/en not_active Ceased
- 2001-08-17 AU AU2001279950A patent/AU2001279950A1/en not_active Abandoned
- 2001-08-17 WO PCT/GB2001/003699 patent/WO2002016344A1/en not_active Ceased
- 2001-08-20 US US09/933,064 patent/US6489343B2/en not_active Expired - Fee Related
- 2001-08-20 PE PE2001000828A patent/PE20020436A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JO2231B1 (en) | 2004-10-07 |
| WO2002016344A1 (en) | 2002-02-28 |
| US6489343B2 (en) | 2002-12-03 |
| US20020035132A1 (en) | 2002-03-21 |
| AU2001279950A1 (en) | 2002-03-04 |
| GB0020721D0 (en) | 2000-10-11 |
| WO2002016343A1 (en) | 2002-02-28 |
| AU2001278626A1 (en) | 2002-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20030471A1 (es) | Compuesto de imidazopiridin como moduladores del receptor 5-ht4 | |
| PE20011371A1 (es) | Derivados de 3-(3-isopropil-5-metil-4h-1,2,4-triazol-4-il)-exo-8-azabiciclo[3.2.1]octano como antagonistas de los receptores de quimiocina ccr5 | |
| PE20020436A1 (es) | Derivados de tetrahidropirano como antagonistas del receptor de neuroquinina 1 (nk-1) | |
| PE20040935A1 (es) | Analogos de 2-quinazolina sustituida-4-ilamina como moduladores de los receptores de capsaicina | |
| AR054035A1 (es) | Derivados benzodioxano y benzodioxolano y uso de los mismos | |
| PE20020753A1 (es) | Heteroaromaticos fusionados como activadores de la glucoquinasa | |
| PE20061106A1 (es) | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida | |
| PE20010854A1 (es) | USO DE DERIVADOS DE PIRIMIDINA 4 SUSTITUIDOS COMO ANTAGONISTAS DE LOS RECEPTORES DE GLUTAMATO mGluR1 | |
| PE20080841A1 (es) | Derivados de quinazolinona e isoquinolinona y su uso para el tratamiento o prevencion de trastornos relacionados con el estres o la depresion | |
| AR042691A1 (es) | Agonistas inversos del receptor cb1 procedimientos de obtencion y composiciones farmaceuticas. | |
| PE20061150A1 (es) | Derivados de n-(n-sulfonilaminoarilmetil)ciclopropanocarboxamida sustituidos como antagonistas del receptor vainilloide tipo 1 (vdr1) | |
| ES2623982T3 (es) | Compuestos heterocíclicos de unión a receptor de quimiocina con eficacia potenciada | |
| PE20011294A1 (es) | Composiciones farmaceuticas de agonistas/antagonistas de estrogeno y estatinas para tratar la osteoporosis y reducir el colesterol | |
| PE20040650A1 (es) | Moduladores del receptor de glucocorticoides | |
| PE20001556A1 (es) | Derivados de tetrahidropirano utiles como antagonistas de taquicinina | |
| PE20070112A1 (es) | Mimeticos de glucocorticoides, metodos para su fabricacion, composiciones farmaceuticas y usos de los mismos | |
| AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
| PE20060383A1 (es) | Nuevos derivados amino de urea ciclicos como inhibidores de quinasa | |
| PE20030762A1 (es) | Compuestos heterociclicos como antagonistas nk1 | |
| PE20041061A1 (es) | Imidazol-4-il-etinil-piridina | |
| PE20021043A1 (es) | DERIVADOS DE PIRAZINO[1,2-a]INDOL COMO AGONISTAS DEL RECEPTOR 5HT2 | |
| AR049696A1 (es) | Derivados de indol | |
| WO2022261240A3 (en) | Dimethoxyphenylalkylamine activators of serotonin receptors | |
| PE20060625A1 (es) | Derivados de benzazepina como antagonistas y/o agonistas del receptor h3 de histamina | |
| PE20081665A1 (es) | Antagonistas del receptor de dopamina 2 de rapida disociacion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |